Literature DB >> 16033820

Analysis of cell cycle regulator proteins in encapsulated thymomas.

Alfonso Baldi1, Vincenzo Ambrogi, Davide Mineo, Pasquale Mellone, Mara Campioni, Gennaro Citro, Tommaso Claudio Mineo.   

Abstract

PURPOSE: Although survival of encapsulated thymomas is usually good, some patients present a higher incidence rate of recurrence and a shorter long-term survival. Abnormalities in the components of cell cycle checkpoints are extremely common among virtually all neoplasms. In this study, three components of the cell cycle machinery (i.e., p21, p27 and p53) were examined in a series of well-characterized encapsulated thymoma specimens to analyze coregulation and influence on recurrence and survival. EXPERIMENTAL
DESIGN: Sixty-eight consecutive patients with thymoma were operated in our center from 1987 to 2000. Expression of p53, p21, and p27 was studied in specimens from 25 encapsulated thymomas using immunohistochemistry. Generic factors and gene expression influencing the probability of recurrence were studied. Positive expression was dichotomized defining positive when present in more than 5% of tumor cells. Mean follow up was 85.9 months; clinical data about recurrence were recorded.
RESULTS: Univariate analysis suggests that positive p53 (P < 0.05), negative p21 (P = 0.01), and especially negative p27 expressions (P = 0.001) significantly correlate with poor prognosis for disease-free survival. Multivariate Cox regression analysis suggests that negative p27 immunohistology is the only significant variable for poor prognosis (P = 0.03; odds ratio, 0.08; 95% confidence interval, 0.01-0.88).
CONCLUSIONS: These results show that loss of control of cell cycle checkpoints is a common occurrence in thymomas and support the idea that functional cooperation between different cell cycle inhibitor proteins constitutes another level of regulation in cell growth control and tumor suppression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033820     DOI: 10.1158/1078-0432.CCR-05-0070

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.

Authors:  Glen J Weiss; Manuel Hidalgo; Mitesh J Borad; Daniel Laheru; Raoul Tibes; Ramesh K Ramanathan; Lisa Blaydorn; Gayle Jameson; Antonio Jimeno; Jeffrey D Isaacs; Angela Scaburri; Maria Adele Pacciarini; Francesco Fiorentini; Marina Ciomei; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2011-12-09       Impact factor: 3.850

2.  Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma.

Authors:  Thaer Khoury; Rameela Chandrasekhar; Gregory Wilding; Dongfeng Tan; Richard T Cheney
Journal:  Int J Exp Pathol       Date:  2010-11-02       Impact factor: 1.925

Review 3.  Expression of cell cycle and apoptosis regulators in thymus and thymic epithelial tumors.

Authors:  Alexandra Papoudou-Bai; Alexandra Barbouti; Vassiliki Galani; Kalliopi Stefanaki; Dimitra Rontogianni; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2015-03-21       Impact factor: 3.984

4.  Protein expression status of p53 and epidermal growth factor receptor in thymoma.

Authors:  Fei Cui; Jianxing He; Jun Liu; Yijiang Chen
Journal:  Oncol Lett       Date:  2011-03-14       Impact factor: 2.967

5.  β-catenin activation drives thymoma initiation and progression in mice.

Authors:  Chih-Chia Liang; Tsai-Ling Lu; Yi-Ru Yu; Li-Ru You; Chun-Ming Chen
Journal:  Oncotarget       Date:  2015-06-10

6.  Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization.

Authors:  Gui Youn Lee; Woo Ick Yang; Hei Cheul Jeung; Sang Chul Kim; Min Young Seo; Chan Hee Park; Hyun Cheol Chung; Sun Young Rha
Journal:  BMC Genomics       Date:  2007-09-03       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.